Imatinib
Imatinib is a targeted kinase inhibitor used for cancers driven by selected molecular abnormalities. It is part of a specialist treatment plan and should not be substituted independently. Listed uses include chronic myeloid leukaemia and gastrointestinal stromal tumour.
Key points
- The cancer diagnosis and molecular target determine whether imatinib is appropriate.
- Blood counts and liver function require monitoring; fluid retention can affect the heart or lungs.
- Strong enzyme inhibitors or inducers can substantially change imatinib exposure.
Listings are for comparison only; suitability and supply depend on oncology prescribing, molecular diagnosis, monitoring and pharmacy checks.
Important safety checks
Review liver, kidney or heart disease, fluid retention, bleeding, infection, pregnancy, fertility and all medicines or supplements. Monitoring follows the cancer regimen.
When to seek urgent care
Follow the oncology plan. Seek urgent help for fever, unusual bleeding, severe breathlessness, rapid swelling or weight gain, chest pain, yellow skin or eyes, facial swelling or breathing difficulty.